Herbst, R. S., Garon, E. B., Kim, D., Chul Cho, B., Pérez Gracia, J. L., Han, J., Dubos Arvis, C., Majem, M., Forster, M., Monnet, I., Novello, S., Szalai, Z., Gubens, M. A., Su, W., Ceresoli, G. L., Samkari, A., Jensen, E., Lubiniecki, G. M., & Baas, P. (n.d.). lBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095517293.0x00003f